指南与共识免疫规划传染病防控与疫情报告卫生政策与健康促进

免疫实践咨询委员会关于5-11岁儿童使用辉瑞-BioNTech COVID-19疫苗的临时推荐——美国,2021年11月

The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021.
指南 / 共识 · MMWR Morb Mortal Wkly Rep · 2021-11-12

辉瑞-BioNTech COVID-19疫苗(BNT162b2)为脂质纳米颗粒配方的核苷修饰mRNA疫苗,编码SARS-CoV-2预融合刺突糖蛋白。2021年10月29日FDA对5-11岁儿童新配方发布紧急使用授权修订,接种2剂(每剂10 μg,0.2 mL),间隔3周。2021年11月2日ACIP发布5-11岁儿童使用该疫苗预防COVID-19的临时推荐,采用EtR框架和GRADE方法,认为益处大于风险。

要点

  • ACIP于2021年11月2日发布5-11岁儿童接种辉瑞-BioNTech COVID-19疫苗的临时推荐。
  • 5-11岁儿童接种2剂(每剂10 μg,0.2 mL),间隔3周。
  • 该疫苗在5-11岁儿童中对COVID-19高效(>90%),ACIP判定获益大于风险。

核心结论

  • ACIP发布临时推荐,5-11岁儿童可使用辉瑞-BioNTech COVID-19疫苗预防COVID-19,该推荐为临时性并将随新信息更新。
  • 该疫苗在5-11岁儿童中对COVID-19高效(>90%),ACIP判定接种获益大于风险。
  • 接种疫苗对保护儿童免患COVID-19和减少SARS-CoV-2社区传播很重要。

研究设计与样本

  • ACIP于2021年11月2日发布临时推荐,采用证据到推荐(EtR)框架并纳入GRADE方法。
  • FDA于2021年10月29日对5-11岁儿童用新配方辉瑞-BioNTech COVID-19疫苗发布紧急使用授权修订。

主要发现

  • 辉瑞-BioNTech COVID-19疫苗在5-11岁儿童中对COVID-19高效(>90%)。
  • ACIP判定5-11岁儿童接种该疫苗的获益大于风险。

关键数值与推荐

  • 5-11岁儿童接种辉瑞-BioNTech COVID-19疫苗:2剂,每剂10 μg(0.2 mL),间隔3周。
  • ≥12岁人群推荐接种2剂(每剂30 μg,0.3 mL),间隔3周。

临床怎么用

  • ACIP临时推荐5-11岁儿童在紧急使用授权下接种辉瑞-BioNTech COVID-19疫苗以预防COVID-19。

局限性

  • ACIP对5-11岁儿童使用该疫苗的推荐为临时性,将随新信息更新。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine is a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine encoding the prefusion spike glycoprotein of SARS-CoV-2, the virus that causes COVID-19. On August 23, 2021, the Food and Drug Administration (FDA) approved a Biologics License Application (BLA) for use of the Pfizer-BioNTech COVID-19 vaccine, marketed as Comirnaty (Pfizer, Inc.), in persons aged ≥16 years (1). The Pfizer-BioNTech COVID-19 vaccine is also recommended for adolescents aged 12-15 years under an Emergency Use Authorization (EUA) (1). All persons aged ≥12 years are recommended to receive 2 doses (30 μg, 0.3 mL each), administered 3 weeks apart (2,3). As of November 2, 2021, approximately 248 million doses of the Pfizer-BioNTech COVID-19 vaccine had been administered to persons aged ≥12 years in the United States.* On October 29, 2021, FDA issued an EUA amendment for a new formulation of Pfizer-BioNTech COVID-19 vaccine for use in children aged 5-11 years, administered as 2 doses (10 μg, 0.2 mL each), 3 weeks apart (Table) (1). On November 2, 2021, the Advisory Committee on Immunization Practices (ACIP) issued an interim recommendation† for use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years for the prevention of COVID-19. To guide its deliberations regarding recommendations for the vaccine, ACIP used the Evidence to Recommendation (EtR) Framework§ and incorporated a Grading of Recommendations, Assessment, Development and Evaluation (GRADE) approach.¶ The ACIP recommendation for the use of the Pfizer-BioNTech COVID-19 vaccine in children aged 5-11 years under an EUA is interim and will be updated as additional information becomes available. The Pfizer-BioNTech COVID-19 vaccine has high efficacy (>90%) against COVID-19 in children aged 5-11 years, and ACIP determined benefits outweigh risks for vaccination. Vaccination is important to protect children against COVID-19 and reduce community transmission of SARS-CoV-2.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Woodworth KR, Moulia D, Collins JP, et al. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34758012. doi:10.15585/mmwr.mm7045e1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。